BMS and Pfizer to present new Eliquis analyses at ESC Congress 2016

Nineteen abstracts to be presented, including new post-hoc sub-analyses from the ARISTOTLE Phase III trial and multiple retrospective real-world data analyses from ACROPOLIS.

“The Bristol-Myers Squibb and Pfizer Alliance is pleased to share 19 abstracts, which include new real-world analyses, as well as new sub-analyses from the pivotal Phase III ARISTOTLE trial,” said Rory O’Connor, Chief Medical Officer, Internal Medicine, Pfizer Innovative Health. “We look forward to the opportunity to contribute to the scientific discussion and continued research during ESC Congress 2016.”

“As patient and provider needs continue to evolve, it’s essential that we deepen our understanding of how medicines are working in real-world situations,” said Jack Lawrence, Vice President, Cardiovascular Specialty Development, Bristol-Myers Squibb. “This year at ESC Congress 2016, we’ll be discussing new NVAF and VTE data that complement our robust body of clinical trial data.”